WORK Medical Technology Group, a leading supplier of medical devices in China, has announced that its subsidiary, Hunan Saitumofei, has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II Artificial Intelligence (AI)-Automated Human Blood Cell Morphology Analyzer. 

 

The approval marks a major milestone in WORK Medical’s research and development strategy and positions the AI-driven device as a potential key growth driver for the company.

 

The analyzer, which combines a main unit with embedded analysis software, integrates an optical imaging system, sample-handling module, barcode scanner, automatic oil-immersion unit, and control board. 

 

It performs white blood cell differential counts and quantifies red blood cell and platelet morphology, providing clinicians with advanced cell morphology screening. 

 

The device leverages AI-powered automation, high-speed digital imaging, and deep-learning algorithms to identify, pre-classify, and describe blood cell morphology—reducing manual workload while boosting efficiency and accuracy. Manufacturing is slated to begin in the first half of 2026.

 

"This new analyzer integrates cutting-edge AI technology into traditional medical testing, improving consistency, efficiency, and accuracy while minimizing manual intervention and associated costs,” said Shuang Wu, CEO and Chairman of WORK Medical. 

 

“The device has progressed from an auxiliary image-reading tool into a fully automated, standardized, and remotely accessible core testing platform. 

 

"With continuous AI-algorithm iteration and pipeline integration, it is expected to become standard equipment in hematology and oncology departments at tertiary hospitals and primary-care laboratories, and is aimed to provide support for early screening of blood disorders, quality-control enhancement, and labor-cost optimization. We are optimistic about this product line’s growth and its revenue potential for the Company.”